<DOC>
	<DOCNO>NCT02595840</DOCNO>
	<brief_summary>The aim Trans-MARBLE identify validate novel biomarkers response resistance maintenance therapy afatinib pemetrexed patient EGFRmutated non-small-cell lung cancer progress first-line therapy afatinib .</brief_summary>
	<brief_title>A Prospective , Multiparametric Biomarker Study Identify Predictors Treatment Response Resistance Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib Pemetrexed With AIO-TRK-0114 Study ( MARBLE )</brief_title>
	<detailed_description>Patients EGFR-mutated non-small-cell lung cancer progress first-line therapy afatinib participate AIO-TRK-0114 ( MARBLE ) study ( EudraCT-No . 2014-001983-36 ) offer participation Trans-MARBLE . If write informed consent grant , archival surplus diagnostic tumor sample , blood sample fresh tumor sample acquire medically indicate diagnostic procedure . All sample pseudonymized ship Coordinating Study Laboratory Biobank ( WBE ) Essen Central ctDNA Sequencing Laboratory Cologne . Biomaterials include DNA , RNA proteins extract subjected genomic , epigenetic proteomic analysis . Assay result report central study data base scientific analysis . In addition , biomarker result obtain NGS-based panel sequence tumor- plasma-derived DNA report back clinical investigator AIO-TRK-0114 ( MARBLE ) study , share study patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Participation AIOTRK0114 ( MARBLE ) study ( EudraCTNo . 201400198336 ) 2 . Written inform consent 1 . Patients meet inclusion criterial AIOTRK0114 ( MARBLE ) study ( EudraCTNo . 201400198336 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>